Thomas J. Parker is a partner in the Intellectual Property Litigation Group. His practice area is pharmaceutical patent litigation under the Hatch–Waxman Act and Biologics Price Competition and Innovation Act (BPCIA). Tom has been a member of Alston & Bird’s Hatch–Waxman practice since 2003.
Over the past 25 years, Tom has represented clients as lead counsel in numerous patent litigations under the Hatch–Waxman Act, related inter partes review proceedings before the PTAB, and actions against the FDA.
With his 25-plus years of litigation experience, together with his advanced science degree and experiences as a research scientist for a major drug company, Tom has the requisite knowledge to assist pharmaceutical and biotechnology companies through the myriad patent and FDA regulatory issues that arise when seeking FDA approval to sell a generic, branded, or biosimilar drug.
He also regularly counsels clients on matters relating to patent prosecution, interferences, freedom to operate, and licensing in a host of areas, including pharmaceuticals, chemical compositions, and biotechnology, as well as medical devices.
He is registered to practice before the U.S. Patent and Trademark Office. Tom publishes and presents at seminars on various patent issues relating to the Hatch–Waxman Act and other patent-related matters.